Emerging Therapies for Relapsed/Refractory Multiple Myeloma.

Citation metadata

Date: May 2022
From: Oncology(Vol. 36, Issue 5)
Publisher: Intellisphere, LLC
Document Type: Article
Length: 3,497 words
Lexile Measure: 1420L

Document controls

Main content

Article Preview :

FACULTY

Sagar Lonial, MD, FACP

Professor and Department Chair Department of Hematology and Medical Oncology Emory University Atlanta, Georgia

This activity was written by PER[R] editorial staff under faculty guidance and review. The Q&A portion of the activity was transcribed from a recorded interview with the faculty and edited by faculty and PER[R] editorial staff for clarity.

CME PROVIDER CONTACT INFORMATION

Physicians' Education Resource[R], LLC

2 Clarke Drive, Suite 110

Cranbury, NJ 08512

Toil-Free: 888-949-0045

Local: 609-378-3701

Fax: 609-257-0705

info@gotoper.com

Upon successful completion of this activity, you should be better prepared to:

* Outline recent clinical data on immunotherapy in patients with relapsed/refractory multiple myeloma (R/R MM)

* Review emerging evidence on the safety and efficacy of chimeric antigen receptor therapy, bispecific antibodies/bispecific T-cell engager therapy, antibody-drug conjugates, and small-molecule inhibitors and modulators

* Discuss emerging trends in R/R MM therapy

RELEASE DATE: May 1,2022

EXPIRATION DATE: May 1,2023

INSTRUCTIONS FOR PARTICIPATION / HOW TO RECEIVE CREDIT

1. Read this activity in its entirety.

2. Go to www.gotoper.com/etrr22mm-art to access and complete the posttest.

3. Answer the evaluation questions.

4. Request credit using the drop-down menu.

You may immediately download your certificate.

FACULTY, STAFF, AND PLANNERS' DISCLOSURES

In accordance with ACCME Guidelines, PER (8) has identified and resolved all C0I for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Disclosures (Dr Lonial): Grant/Research Support: Takeda Oncology, Novartis, Bristol Myers Squibb, Janssen, C4 Therapeutics; Consultant: Janssen, Bristol Myers Squibb, Novartis, GlaxoSmiMline, Am gen, Celgene, Takeda Oncology; Board of Directors with Stock TG Therapeutics.

The staff of PER (8) have no relevant financial relationships with commercial interests to disclose.

OFF-LABEL DISCLOSURE AND DISCLAIMER

This activity mayor may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this activity is for accredited continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER (8) or any of the companies that provided commercial support forthis activity.

This activity is funded by PER[R].

ACCREDITATION/CREDIT DESIGNATION

Physicians' Education Resource (8) , LLC, is accredited bythe Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource (8) , LLC, designates this enduring material for a maximum of 0.5AMA PRA Category 1 Credits[TM]. Physicians should claim onlythe credit commensurate with the extent of their participation in the activity.

The treatment landscape for relapsed and refractory multiple myeloma (R/RMM) is undergoing a dramatic expansion. Recent FDA approvals of several novel drugs have provided new options for patients with late stages of disease.

The XPO1 nuclear export inhibitor selinexor was approved in July 2019. Belantamab mafodotin (belamaf) became the first approved antibody-drug conjugate (ADC) in August 2020. In March 2021, idecabtagene vicleucel (ide-cel) ushered in...

Source Citation

Source Citation   

Gale Document Number: GALE|A704419384